Skip to content

Stereotactic ablation of Hypothalamic hamartomas for seizure treatment

Stereotactic ablation of Hypothalamic hamartomas for seizure treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-7m2rmr
Enrollment
Unknown
Registered
2019-06-18
Start date
2010-02-02
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

Retrospective study that included sequentially seven patients with hypothalamic hamartoma, who were submitted to radiofrequency ablation. Clinical evaluation and follow-up were held using related epil
Procedure/surgery

Sponsors

Universidade de São Paulo
Lead Sponsor
Universidade de São Paulo
Collaborator

Eligibility

Age
13 Years to 50 Years

Inclusion criteria

Inclusion criteria: Age between 13 and 50 years old, hypothalamic hamartoma identified on magnetic ressonance imaging and presence of refractory gelastic seizures

Exclusion criteria

Exclusion criteria: Alcohol Abuse, medication, or dependence on illicit substances in the Last 12 Months, clinically relevant lesions (other tumors than hypothalamic hamartoma, for example) in preoperative magnetic resonance imaging, patients undergoing chemotherapy for treatment of malignant tumors or who require chronic oral or intravenous treatment with immunosuppressants or steroids, patients unable to comply with schedule of study visits and timetable, lactating patients or with positive pregnancy test, other medical conditions that require probable hospitalization during the study, cronic infection, to have any metallic implant in the brain and current participation in another study of device investigation or drugs testing or surgeries of any nature.

Design outcomes

Primary

MeasureTime frame
Control evaluation of gelastic and non gelastic seizures.

Secondary

MeasureTime frame
Volumetric and morphological evaluation through magnetic resonance imaging.;Evaluation of the hormonal profile through the serum dosage.;Evaluation of the global improvement measured by the Global Clinical Impression scale.

Countries

Brazil

Contacts

Public ContactMiguel Ernesto San Martin Sepulveda

Universidade de São Paulo

smspolaris@gmail.com19992197720

Outcome results

None listed

Source: REBEC (via WHO ICTRP)